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Abstract 
Background: Numerous worldwide clinical trials have proven the indisputably negative 
influence of morphine on the pharmacokinetics and pharmacodynamics of P2Y12 receptor 
inhibitors in patients presenting with acute coronary syndromes. The aim of this trial was to 
evaluate whether oral co-administration of an anti-opioid agent, naloxone, can be considered a 
successful approach to overcome ‘the morphine effect’.  
Methods: Consecutive unstable angina patients receiving ticagrelor and morphine with or 
without orally administered naloxone underwent assessment of platelet reactivity using 
Multiplate analyzer as well as evaluation of the pharmacokinetic profile of ticagrelor and its 
active metabolite, AR-C124910XX, at nine pre-defined time points within the first 6 hours 
following oral intake of the ticagrelor loading dose.  
Results: The trial shows no significant differences regarding the pharmacokinetics of 
ticagrelor between both study arms throughout the study period. AR-C124910XX plasma 
concentration was significantly higher 120 min after the ticagrelor loading dose 
administration (p = 0.0417). However, the evaluation of pharmacodynamics did not show any 
statistically significant differences between the study arms. 
Conclusions: To conclude, this trial shows that naloxone co-administration in ticagrelor-
treated acute coronary syndrome patients on concomitant treatment with morphine shows no 
definite superiority in terms of ticagrelor pharmacokinetic and pharmacodynamic profile.  
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Introduction 
The development of contemporary treatment of acute coronary syndromes (ACS) has 
forced the establishment of methods of rapid platelet inhibition. The results of the PLATO 
trial proved the superiority of ticagrelor over well-known and widely used clopidogrel in 
terms of its effectiveness, mainly demonstrated by the reduction of the composite endpoint 
including cardiovascular death, myocardial infarction or stroke with no significant increase of 
the risk of clinically significant bleeding [1]. Based on those findings ticagrelor has become 
the treatment of choice in patients presenting with ACS according to currently available 
guidelines [2–6].   
Numerous ACS patients, especially those presenting with ST-segment elevation 
myocardial infarction (STEMI), require strong and effective analgesia. The most commonly 
used analgesic medication nowadays is morphine [2]. Morphine administration used to be 
considered beneficial for ACS patients as it was thought to be associated not only with pain 
alleviation, but also with a positive tranquilizing effect on treated individuals. Several 
international studies however, have revealed a negative interaction between morphine and 
P2Y12 receptor inhibitors leading to decrease of the plasma concentrations of those platelet 
inhibitors and their metabolites as well as delay and attenuation of their antiplatelet activity. 
[7–11]. The discovery of the negative influence of morphine on the PK/PD profile of 
ticagrelor in ACS patients resulted in a decrease of class of recommendation for morphine use 
to class IIa for STEMI based on the latest guidelines [2]. Morphine has been found to 
negatively influence gastric emptying, impair intestinal motility, reduce intestinal secretion 
and induce nausea or vomiting [12]. The phenomenon presented above can be called ‘the 
morphine effect’. 
Naloxone, a selective opioid receptor antagonist, is widely used to diminish negative 
effects of opioid drugs. Its utility is most pronounced in opioid substitution therapy in cases of 
opioid addiction or reversal of opioid action in opioid intoxication. Typically, in such clinical 
situations, naloxone is administered parenterally. However, if administered orally, it has been 
proven to successfully reduce the negative impact on gastrointestinal tract by relieving opioid-
related constipation in oncological patients requiring regular opioid administration. This 
approach allows the elimination of intestinal motility impairment without risking attenuation 
of the analgesic activity of an opioid, as naloxone administered orally is associated with a 
strong first-pass effect making its serum concentration barely detectable. The final 
bioavailability of the drug after oral administration ranges from 2% to 3% [13–16].   
On the basis of the aforementioned findings it was hypothesized that co-administration 
of naloxone may prove beneficial as a potential method of overcoming ‘the morphine effect’ 
in ACS patients treated with ticagrelor who received morphine. 
 
Methods 
Study design and population 
A pharmacokinetic/pharmacodynamic, phase IV, single center, investigator-initiated, 
randomized, open-label, active-controlled trial was designed and it was conducted in 
accordance with Good Clinical Practice and the Declaration of Helsinki guidelines. The 
previously published study protocol [17] was approved by The Ethics Committee of The 
Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz (approval 
number KB 540/2015). Any study-related procedures were undertaken only after obtainment 
of informed consent to participate in the trial from each study participant. Males and non-
pregnant females, aged 18–80 years, admitted to the Department of Cardiology, A. Jurasz 
University Hospital in Bydgoszcz, Poland due to unstable angina and qualified for coronary 
angiography, underwent eligibility screening. The complete list of inclusion and exclusion 
criteria is presented in Figure 1. 
Patients admitted to the Department of Cardiology, due to unstable angina received 
orally a 300 mg loading dose (LD) of plain acetylsalicylic acid (Polpharma SA, Starogard 
Gdanski, Poland) and underwent eligibility screening for participation in the study. Having 
consented to participate in the trial, eligible patients were randomized in a 1:1 ratio into two 
study arms as follows — the active study arm including patients receiving: 1) crushed tablets 
of 180 mg ticagrelor in 10 mL suspension in tap water administered orally; 2) 5 mg of 
morphine administered intravenously; 3) 1 mg of naloxone administered orally; and the 
control group treated with: 1) crushed tablets of 180 mg ticagrelor in 10 mL suspension in tap 
water administered orally; and 2) 5 mg of morphine administered intravenously. The Random 
Allocation Software version 1.0. was used for the process of randomization. 
Based on the results of studies previously conducted in the present department, oral 
administration of crushed ticagrelor was chosen as it was associated with the optimal 
pharmacokinetic and pharmacodynamic profile in unstable angina patients [18]. Only patients 
with low and intermediate risk of in-hospital mortality as assessed with the GRACE scale 
were enrolled in the study, which allowed completion of the whole blood sampling schedule 
before coronary angiography, avoiding the risk of its unpredictable impact on platelet 
function. Taking into account that morphine negatively affects the absorption of ticagrelor 
from the gastrointestinal tract, we assumed that addition of an opioid antagonist, naloxone 
administered orally, would contribute to the optimization of the PK/PD profile of ticagrelor 
and its active metabolite. As assessed in previous studies, a group of 15 patients for each 
study arm was considered to be sufficient for statistical analysis. 
 
Blood sample collection 
According to the study protocol, following obtainment of informed consent for 
participation in the study and randomization into the study arms, collection of blood samples 
for the pharmacokinetic and pharmacodynamic assessment was done. Nine predefined time 
points of blood sampling were as follows: before the administration of ticagrelor loading dose 
and 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h after its administration. 
 
Pharmacokinetics 
Pharmacokinetic assessment was performed for each study participant at all predefined 
time points. Plasma concentrations of ticagrelor and its active metabolite were evaluated in 
The Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus 
University, Bydgoszcz using liquid chromatography and mass spectrometry. Measurements 
were performed using Shimadzu UPLC Nexera X2 system and Shimadzu 8030 ESI-Triple 
Quadrupole mass spectrometer. The limits of quantification for ticagrelor and its active 
metabolite were defined as 4.69 ng/mL. 
 
Pharmacodynamics 
The evaluation of pharmacodynamics was performed using the Multiplate analyzer 
(ADPtest, Roche Diagnostics, Switzerland). The measurements of platelet reactivity were 
conducted with multiple electrode aggregometry (MEA) at all time points as mentioned 
above. Area under the aggregation curve (AUC) as a parameter reflecting the overall exposure 
to both ticagrelor and AR-C124900XX, was assessed on the assumption that AUC > 46 units 
(U) was defined as high platelet reactivity (HPR). 
 
Study outcomes 
According to the protocol, the primary endpoint of this PK/PD study was the time 
required to reach the maximum plasma concentration of ticagrelor and AR-C124900XX 
following ticagrelor loading dose intake. Secondary endpoints included maximum 
concentration of ticagrelor and its metabolite, area under the plasma concentration-time curve 
(AUCCT) for ticagrelor and AR-C124900XX and platelet reactivity assessed by MEA in the 
aforementioned time points. The complete list of study outcomes is presented in Figure 2.  
 
Statistical analysis 
Statistical analysis was performed using Matlab R2014 Software (Mathworks, Natick, 
MA, USA), the Statistica 12.5 package (StatSoft, Tulsa, OK, USA) and R version 3.5.0 (R: 
library lme). P < 0.05 were considered statistically significant. AUC was calculated using the 
trapezoidal rule. Comparative analysis of pharmacokinetic parameters between the study arms 
and time points were conducted using mixed models with random effects with the maximum 
likelihood method applied for estimating variance parameters. Comparison of 
pharmacodynamic parameters between the study arms was performed with the Fisher exact 
test. 
 
Results 
Population baseline characteristics 
Between October 2016 and December 2018, a total of 30 unstable angina (UA) 
patients were enrolled in the study. Baseline serum troponin evaluation required ruling out an 
acute myocardial infarction was performed for each study participant showing no case of 
elevation above the reference level of 34.5 ng/L and 15.6 ng/L for men and women, 
respectively. The study population was generally well balanced, except for the prevalence of 
prior coronary artery disease and consequently prior percutaneous coronary intervention 
(PCI), which were noticeably higher in the study arm (66.7% vs. 28.6%, p = 0.04 and 53.3% 
vs. 14.3%, p = 0.03, respectively). The study population baseline characteristics are presented 
in Figure 3. 
 
Safety and tolerability evaluation 
The safety evaluation did not reveal any case of serious adverse events such as death, 
myocardial infarction, stent thrombosis, stroke or thromboembolic events throughout the 
study. Minor symptoms including weakness and headache were reported by 2 patients in the 
active arm. On the other hand, adverse effects in the control group of participants included 
mild bradycardia (50–55 bpm), nausea (2 patients) and excessive sweating associated with 
feeling unwell (1 patient). Due to vomiting that required immediate administration of 
metoclopramide, a prokinetic drug, 1 patient’s participation in the trial was terminated, which 
resulted in exclusion of the initially obtained results of pharmacokinetics and 
pharmacodynamics of this participant from statistical analysis.  
 
Pharmacokinetics 
Pharmacokinetic assessment was performed for each study participant. Statistical 
analysis of all results showed only a trend toward a better PK profile in the naloxone arm. 
Mixed models with random effects showed no significant differences between the study arms 
in terms of ticagrelor-related parameters. However, the difference between plasma 
concentrations of AR-C124910XX obtained at 120 min following ticagrelor LD reached 
statistical significance (p=0.0417). PK parameters obtained throughout the study are presented 
in Figure 4. Mean concentration of ticagrelor and its active metabolite is presented in Figures 
5 and 6. 
 
Pharmacodynamics 
The PD evaluation was performed for each patient, revealing no significant differences 
between the study arms. The superiority of the naloxone arm in terms of percentage of HPR 
patients at particular time points patients was only numerical. The most pronounced 
difference was observed at 30 minutes following ticagrelor LD (7 vs. 10 patients) for the 
naloxone and control arm respectively (p = 0.18; Fig. 7). 
 Discussion 
The recent discovery of the so-called ‘morphine effect’ brought new challenges into 
contemporary ACS treatment strategies. As mentioned before, co-administration of morphine 
in the course of ACS is no longer a first-line approach due to its negative impact on P2Y12 
receptor inhibitors PK/PD profile. Inevitably, some patients, especially presenting with 
STEMI, will require strong analgesic agents to relieve unbearable pain associated with the 
infarction. Until now, several approaches to reduce ‘the morphine effect’ have been described 
in the literature.  
The present study is the first one aiming to assess the influence of oral naloxone on 
ticagrelor and AR-C124900XX in ACS patients who received morphine. The results show no 
definite benefit in terms of the PK and PD profile of ticagrelor in the naloxone arm, however 
a trend toward improvement of analyzed parameters could be observed.  
In one previous study it was proved that co-administration of an anti-emetic agent, 
metoclopramide, leads to higher plasma concentrations of ticagrelor and its active metabolite 
and reduction of time required to reach maximum plasma concentrations of ticagrelor and its 
metabolite (123 min vs. 168 min for control arm, p = 0.015) [19].  
The PK/PD profile of currently used P2Y12 receptor inhibitors has also been found to be 
noticeably dependent on the administration strategy of the drug. No inconsistencies can be 
found in terms of the administration of crushed tablets of P2Y12 inhibitors. Zafar et al. proved 
that the administration of clopidogrel in healthy volunteers was associated with faster and 
greater bioavailability if the drug was given as a crushed form via a nasogastric tube [20]. 
According to a study by Rollini et al. [21], administration of crushed prasugrel in STEMI 
patients led to faster absorption of this agent. Also, it was associated with higher plasma 
concentrations of its metabolite and reduction of platelet reactivity 30 min after the LD of 
prasugrel. In the MOHITO study, Parodi et al. [22] reported that the time required to achieve 
platelet inhibition in STEMI patients was significantly shorter if they received crushed 
ticagrelor instead of standard integral tablets. Oral administration of crushed ticagrelor was 
also associated with the best PK/PD profile of ticagrelor and its active metabolite in a 
previous study evaluating the influence of ticagrelor administration strategy in patients 
presenting with UA. Moreover, the above-mentioned study demonstrated this strategy to be 
superior over sublingual administration of crushed ticagrelor [18].  
The results of the latest studies aiming to evaluate the impact of ticagrelor 
administration strategy on its PK/PD profile show superiority of chewed ticagrelor in terms of 
platelet reactivity units (PRU) measured with VerifyNow in non-STEMI patients at 1 hour 
where it was found to be significantly lower [23]. In a study by Venetsanos et al. [24] PRU 
were also significantly lower in patients presenting with stable angina pectoris in the chewed-
ticagrelor arm in comparison with integral ticagrelor arm.  
 
Limitations of the study 
The study population comprised only unstable angina patients, thus baseline platelet 
reactivity does not fully reflect characteristics of STEMI patients. A limited number of study 
participants might have negatively influenced the statistical analysis as only a trend toward 
improvement of the PK profile could be observed in the naloxone arm. Although the 
prevalence of prior coronary artery disease in the naloxone group was higher than in the 
control group, it did not affect baseline platelet reactivity.  
 
Conclusions 
According to available research, this study is the first one to evaluate the impact of an 
anti-opioid drug, naloxone, on PK and PD of ticagrelor and its active metabolite. Even though 
a trend toward improvement of the PK/PD profile of ticagrelor in ACS patients pre-treated 
with morphine followed by oral naloxone is perceptible, further research is required to 
determine optimal approaches to overcome the ‘morphine effect’. 
 
Conflict of interest: Malwina Barańska received honoraria for lectures from Astra Zeneca. 
Bernd Jilma has served as a consultant to and in advisory boards of AstraZeneca. Jacek 
Kubica delivered a lecture for AstraZeneca. All of the other authors declare no potential 
conflict of interests regarding publication of this paper. 
 
References 
1. Cannon C, Harrington R, James S, et al. Comparison of ticagrelor with clopidogrel in 
patients with a planned invasive strategy for acute coronary syndromes (PLATO): a 
randomised double-blind study. The Lancet. 2010; 375(9711): 283–293, doi: 
10.1016/s0140-6736(09)62191-7. 
2. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC 
Guidelines for the management of acute myocardial infarction in patients presenting 
with ST-segment elevation: The Task Force for the management of acute myocardial 
infarction in patients presenting with ST-segment elevation of the European Society of 
Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177, doi: 10.1093/eurheartj/ehx393, 
indexed in Pubmed: 28886621. 
3. Roffi M, Patrono C, Collet JP, et al. ESC Scientific Document Group . 2015 ESC 
Guidelines for the management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation: Task Force for the Management of Acute 
Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation 
of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267–315, doi: 
10.1093/eurheartj/ehv320, indexed in Pubmed: 26320110. 
4. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the 
guideline for the management of patients with unstable angina/Non-ST-elevation 
myocardial infarction (updating the 2007 guideline and replacing the 2011 focused 
update): a report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012; 60: 645–81. 
5. O'Gara PT, Kushner FG, Ascheim DD, et al. American College of Cardiology 
Foundation, American Heart Association Task Force on Practice Guidelines, 
American College of Emergency Physicians, Society for Cardiovascular Angiography 
and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation 
myocardial infarction: executive summary: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines: developed in collaboration with the American College of Emergency 
Physicians and Society for Cardiovascular Angiography and Interventions. Catheter 
Cardiovasc Interv. 2013; 82(1): E1–27, doi: 10.1002/ccd.24776, indexed in Pubmed: 
23299937. 
6. Kubica J, Adamski P, Paciorek P, et al. Treatment of patients with acute coronary 
syndrome: Recommendations for medical emergency teams: Focus on antiplatelet 
therapies. Updated experts' standpoint. Cardiol J. 2018; 25(3): 291–300, doi: 
10.5603/CJ.a2018.0042, indexed in Pubmed: 29671864. 
7. Meine TJ, Roe MT, Chen AY, et al. CRUSADE Investigators. Association of 
intravenous morphine use and outcomes in acute coronary syndromes: results from the 
CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6): 1043–1049, 
doi: 10.1016/j.ahj.2005.02.010, indexed in Pubmed: 15976786. 
8. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor 
exposure and action in patients with myocardial infarction: the randomized, double-
blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016; 37(3): 245–252, doi: 
10.1093/eurheartj/ehv547. 
9. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed 
activity of oral antiplatelet agents in patients with ST-elevation acute myocardial 
infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc 
Interv. 2015; 8(1), doi: 10.1161/CIRCINTERVENTIONS.114.001593, indexed in 
Pubmed: 25552565. 
10. Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and 
effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014; 
63(7): 630–635, doi: 10.1016/j.jacc.2013.10.068, indexed in Pubmed: 24315907. 
11. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor 
concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. 
Eur J Clin Invest. 2015; 46(1): 7–14, doi: 10.1111/eci.12550. 
12. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral 
P2Y12 receptor inhibitors. Int J Cardiol. 2016; 215: 201–208, doi: 
10.1016/j.ijcard.2016.04.077, indexed in Pubmed: 27128531. 
13. Greenwood-Van Meerveld B, Gardner CJ, Little PJ, et al. Preclinical studies of 
opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 
2004; 16 Suppl 2: 46–53, doi: 10.1111/j.1743-3150.2004.00555.x, indexed in 
Pubmed: 15357851. 
14. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in 
healthy subjects. Int J Clin Pharmacol Ther. 2012; 50(5): 360–367, doi: 
10.5414/cp201646, indexed in Pubmed: 22541841. 
15. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, 
focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002; 24(1): 
71–90, doi: 10.1016/s0885-3924(02)00424-4, indexed in Pubmed: 12183097. 
16. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related 
constipation in patients with advanced cancer. Palliat Med. 1996; 10(2): 135–144, doi: 
10.1177/026921639601000208, indexed in Pubmed: 8800821. 
17. Barańska M, Niezgoda P, Kubica J. The influence of naloxone on pharmacokinetics 
and pharmacodynamics of ticagrelor in patients with unstable angina pectoris 
receiving concomitant treatment with morphine — a protocol of a randomized trial. 
Med Res J. 2018, doi: 10.5603/mrj.a2018.0035. 
18. Niezgoda P, Sikora J, Barańska M, et al. Crushed sublingual versus oral ticagrelor 
administration strategies in patients with unstable angina. A 
pharmacokinetic/pharmacodynamic study. Thromb Haemost. 2017; 117(4): 718–726, 
doi: 10.1160/TH16-08-0670, indexed in Pubmed: 28203684. 
19. Sikora J, Niezgoda P, Barańska M, et al. METoclopramide Administration as a 
Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable 
Angina PectorIS-The METAMORPHOSIS Trial. Thromb Haemost. 2018; 118(12): 
2126–2133, doi: 10.1055/s-0038-1675605, indexed in Pubmed: 30453344. 
20. Zafar MU, Farkouh ME, Fuster V, et al. Crushed clopidogrel administered via 
nasogastric tube has faster and greater absorption than oral whole tablets. J Interv 
Cardiol. 2009; 22(4): 385–389, doi: 10.1111/j.1540-8183.2009.00475.x, indexed in 
Pubmed: 19496900. 
21. Rollini F, Franchi F, Angiolillo DJ, et al. Crushed prasugrel tablets in patients 
with STEMI undergoing primary percutaneous coronary intervention: the CRUSH 
study. J Am Coll Cardiol. 2016; 67(17): 1994–2004, doi: 10.1016/j.jacc.2016.02.045, 
indexed in Pubmed: 27012781. 
22. Parodi G, Xanthopoulou I, Bellandi B, et al. Ticagrelor crushed tablets administration 
in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015; 65(5): 511–512, doi: 
10.1016/j.jacc.2014.08.056, indexed in Pubmed: 25660931. 
23. Asher E, Frydman S, Katz M, et al. Chewing versus swallowing ticagrelor to 
accelerate platelet inhibition in acute coronary syndrome - the CHEERS study. For the 
PLATIS (platelets and thrombosis in sheba) study group. Thromb Haemost. 2017; 
117(4): 727–733, doi: 10.1160/TH16-09-0728, indexed in Pubmed: 28150850. 
24. Venetsanos D, Sederholm Lawesson S, Swahn E, et al. Chewed ticagrelor tablets 
provide faster platelet inhibition compared to integral tablets: The inhibition of platelet 
aggregation after administration of three different ticagrelor formulations (IPAAD-
Tica) study, a randomised controlled trial. Thromb Res. 2017; 149: 88–94, doi: 
10.1016/j.thromres.2016.10.013, indexed in Pubmed: 27773347. 
 
 
 
 
Figure 1. A complete list of inclusion/exclusion criteria for the study. 
Inclusion criteria (all criteria must be met) 
Provision of informed consent prior to any study specific procedures 
Diagnosis of unstable angina 
Male or non-pregnant female, aged 18–80 years 
Provision of informed consent for angiography and percutaneous coronary intervention 
GRACE score < 140 patients 
Exclusion criteria (none of the criteria can be met) 
Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before study 
enrollment 
Current treatment with morphine or any opioid “mi” receptor agonist 
Hypersensitivity to ticagrelor 
Current treatment with oral anticoagulant or chronic therapy with low-molecular-weight 
heparin 
Active bleeding 
History of intracranial hemorrhage 
Recent gastrointestinal bleeding (within 30 days) 
History of coagulation disorders 
Platelet count less than 100 × 103/mcl 
Hemoglobin concentration less than 10.0 g/dL 
History of moderate or severe hepatic impairment 
History of major surgery or severe trauma (within 3 months) 
Risk of bradycardic events as judged by the investigator 
Second- or third-degree atrioventricular block during screening for eligibility 
History of asthma or severe chronic obstructive pulmonary disease 
Kidney disease requiring dialysis 
Manifest infection or inflammatory state 
Killip class III or IV during screening for eligibility 
Respiratory failure 
History of severe chronic heart failure (NYHA class III or IV) 
Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, 
voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, 
  
Figure 2. Complete list of study outcomes. 
  
indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, 
dexamethasone, phenobarbital) within 14 days and during study treatment 
Body weight below 50 kg 
Study primary outcome 
Time to maximum concentration (tmax) for ticagrelor and AR-C124900XX 
Study secondary outcomes 
Maximum ticagrelor and AR-C124900XX concentration  
Area under the plasma concentration-time curve for ticagrelor (AUC 0–6 h) 
Area under the plasma concentration-time curve for AR-C124900XX (AUC 0–6h) 
Platelet reactivity assessed by multiple electrode aggregometry 
Figure 3.  Study population baseline characteristics. 
 
 Study group 
(%) 
[n = 15] 
Control group 
(%) 
[n = 14] 
P 
Age [years] 66.87* 60.21* 0.56 
Male 12 (80) 7 (50) 0.089 
Body weight [kg] 88.73* 77.48* 0.25 
Body mass index [kg/m2] 29.05* 27.24* 0.89 
Prior CAD 10 (66.7) 4 (28.6) 0.04 
Prior AMI 8 (53.3) 3 (21.4) 0.08 
Prior PCI 8 (53.3) 2 (14.3) 0.03 
Prior CABG 3 (20.0) 3 (21.4) 0.95 
Arterial hypertension 12 (80.0) 9 (64.3) 0.34 
Prior peptic ulcer disease 3 (20.0) 1 (7.1) 0.31 
Prior GI bleeding 1 (6.7) 1 (7.1) 0.96 
Prior stroke/TIA 2 (13.3) 1 (7.1) 0.59 
CKD  0 1 (7.1) 0.29 
Hyperlipidemia  13 (86.7) 12 (85.7) 0.94 
Current smoker 1 (6.7) 3 (21.4) 0.23 
History of smoking 8 (53.3) 4 (28.6) 0.18 
Family history of CAD 5 (33.3) 9 (64.3) 0.09 
Diabetes mellitus 3 (20.0) 4 (28.6) 0.59 
Insulin therapy  0 3 (21.4) 0.06 
COPD  0 1 (7.1) 0.30 
Peripheral atherosclerosis  3 (20.0) 2 (14.3) 0.68 
*Data are shown as mean. AMI — acute myocardial infarction; CABG — coronary artery bypass grafting; CKD 
— chronic kidney disease; COPD — chronic obstructive pulmonary disease; CAD — coronary artery disease; 
EF — ejection fraction; PCI — percutaneous coronary intervention; TIA — transient ischemic attack 
  
Figure 4. Pharmacokinetic parameters of ticagrelor and AR-C124910XX in mixed 
model with random effects. 
 Value Standard error  P-value 
Ticagrelor 
Intercept –274.1965 184.04303 0.1377 
Time 15 vs. time 0 14.0322 223.66104 0.9500 
Time 30 vs. time 0 145.4685 223.66104 0.5161 
Time 45 vs. time 0 451.1968 223.66104 0.0449 
Time 60 vs. time 0 762.1987 223.66104 0.0008 
Time 120 vs. time 0 694.5401 223.66104 0.0022 
Time 180 vs. time 0 880.6841 223.66104 0.0001 
Time 240 vs. time 0 832.2042 223.66104 0.0003 
Time 360 vs. time 0 589.4043 223.66104 0.0090 
Group I vs. group II 79.2077 45.08410 0.0803 
Time 15 group 5.8586 58.01639 0.9197 
Time 30 group 30.3315 58.01639 0.6016 
Time 45 group 40.3730 58.01639 0.4872 
Time 60 group 31.6464 58.01639 0.5860 
Time 120 group 82.9364 58.01639 0.1543 
Time 180 group –7.0878 58.01639 0.9029 
Time 240 group -4.6060 58.01639 0.9368 
Time 360 group 24.9611 58.01639 0.6674 
Metabolite 
Intercept –48.18294 39.93862 0.2290 
Time 15 vs. time 0 0.00000 49.98636 1.0000 
Time 30 vs. time 0 –3.58612 49.98636 0.9429 
Time 45 vs. time 0 17.25228 49.98636 0.7303 
Time 60 vs. time 0 66.51414 49.98636 0.1847 
Time 120 vs. time 0 160.11218 49.98636 0.0016 
Time 180 vs. time 0 229.63223 49.98636 0.0000 
Time 240 vs. time 0 258.55988 49.98636 0.0000 
Time 360 vs. time 0 177.13110 49.98636 0.0005 
Group I vs. group II 13.79099 9.97219 0.1681 
Time 15 group 0.00000 12.96617 1.0000 
Time 30 group 4.96449 12.96617 0.7022 
Time 45 group 14.83565 12.96617 0.2538 
Time 60 group 19.00707 12.96617 0.1441 
Time 120 group 26.55748 12.96617 0.0417 
Time 180 group 6.51674 12.96617 0.6158 
Time 240 group –4.16173 12.96617 0.7485 
Time 360 group 8.45659 12.96617 0.5150 
 
 
 
 
 
Figure 5. Mean ticagrelor plasma concentration throughout the study; tica — ticagrelor; mf — 
morphine. 
 
 
 
  
Figure 6. Mean concentration of the active metabolite, AR-C124910XX throughout the 
study; tica — ticagrelor; mf — morphine. 
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Figure 7. Proportion of patients with high platelet reactivity in study time points.  
 
 
 
 
 
 
